Pooja Phull, MD

Dr Phull reviews findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma.

Pooja Phull, MD, discusses the rationale for assessing CAR T-cell therapy in the real-world vs trial setting in relapsed/refractory multiple myeloma.

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Pooja Phull, MD, discusses the use of ciltacabtagene autoleucel and idecabtagene vicleucel in R/R multiple myeloma.